"In gRED we share a passion to translate the biggest scientific advances of today into the best possible drugs of tomorrow."
I joined gRED in 2014 to lead the Translational Immunology department and find the research environment at Genentech incredibly rewarding. I enjoy the challenge of working across multiple areas of unmet medical need alongside some of the best and brightest scientists. I was drawn to industry research early in my career through a fruitful collaboration as a PhD student in the Autoimmunity and Transplantation department at the Walter and Eliza Hall Institute (WEHI). After a postdoc I moved from WEHI to DNAX in Palo Alto California (now Merck) to further my experience in early stage drug discovery. There we performed pioneering work on cytokine and T cell biology that underpins several new drug targets still being pursued today. I then joined CSL ltd in Parkville Australia where I continued to employ numerous in-vivo models to understand cellular and subcellular mechanisms of Autoimmunity, Inflammation, Fibrosis, Coagulation, Cancer, Metabolism & Vaccine responses.
Cell Death Differ. 2016 Sep 1;23(9):1565-76.
Here in the Translational Immunology Department we use cutting edge methods and technologies to understand how molecular and cellular pathways contribute to disease pathogenesis in inflammatory, fibrotic, infectious and ocular diseases. We use in-vivo modeling to test new hypotheses, evaluate efficacy, understand drug safety and benchmark new therapies. We work on both early as well as late stage drug targets throughout our small and large molecule portfolio and enjoy collaborations with almost every other department here in gRED.